Timing Matters: Tacrolimus Variability and Rejection in a Chinese Kidney Transplant Cohort

446 kidney transplant recipients from a single-center retrospective study (2016-2021) were analyzed for tacrolimus intra-patient variability. The study, authored by Xuebin Wang, identifies the first 7 postoperative months as the earliest predictive window for donor-specific antibody development. Cumulative incidences of dnDSA and overall rejection were 16.37% and 17.04%, respectively.

Use Cases

• Predicting de novo donor-specific antibody development based on early tacrolimus intra-patient variability.
• Assessing the risk of antibody-mediated rejection based on dnDSA status.
• Evaluating the association between tacrolimus variability in different post-transplant windows and overall rejection risk.
• Investigating the impact of CYP3A5*3 and CYP3A4*1G genetic polymorphisms on drug exposure variability.

Strengths

• Contains data on 446 kidney transplant recipients.
• Includes longitudinal tacrolimus trough concentration measurements up to 24 months post-transplant.
• Reports specific cumulative incidence rates for dnDSA (16.37%) and rejection (17.04%).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is from a single-center study, which may limit generalizability.

Provenance

Source

figshare, author Xuebin Wang.

Collection Method

Single-center retrospective study of kidney transplant recipients.

Time Range

Data collection from 2016 to 2021.

Freshness

Last updated 2026-05-11 04:23:51; freshness should be verified.

Geography

Chinese kidney transplant cohort.